版本:
中国

BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140

April 4 Cyclacel Pharmaceuticals Inc

* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140

* Cyclacel -study concluded cyc140 is a selective plk1 inhibitor which preferentially induces growth inhibition and cell death in malignant versus non-malignant cells Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐